Substances, mixtures and exposure circumstances in this list have been classified by the IARC as Group 1: The agent (mixture) is carcinogenic to humans. The exposure circumstance entails exposures that are carcinogenic to humans. This category is used when there is sufficient evidence of carcinogenicity in humans. Exceptionally, an agent (mixture) may be placed in this category when evidence of carcinogenicity in humans is less than sufficient but there is sufficient evidence of carcinogenicity in experimental animals and strong evidence in exposed humans that the agent (mixture) acts through a relevant mechanism of carcinogenicity.
[edit] Agents and groups of agents
- 4-Aminobiphenyl
- Aristolochic acid
- Arsenic and arsenic compounds1
- Asbestos
- Azathioprine
- Benzene
- Benzidine
- Benzo[a]pyrene
- Beryllium and beryllium compounds2
- Chlornapazine (N,N-Bis(2-chloroethyl)-2-naphthylamine)
- Bis(chloromethyl)ether
- Chloromethyl methyl ether
- 1,3-Butadiene
- 1,4-Butanediol dimethanesulfonate (Busulphan, Myleran)
- Cadmium and cadmium compounds2
- Chlorambucil
- Methyl-CCNU (1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea; Semustine)
- Chromium(VI) compounds2
- Ciclosporin
- Contraceptives, hormonal, combined forms (those containing both estrogen and a progestogen)3
- Contraceptives, oral, sequential forms of hormonal contraception (a period of estrogen-only followed by a period of both estrogen and a progestogen)
- Cyclophosphamide
- Diethylstilboestrol
- Dyes metabolized to benzidine
- Epstein-Barr virus
- Estrogens, nonsteroidal 1
- Estrogens, steroidal 1
- Estrogen therapy, postmenopausal
- Ethanol in alcoholic beverages
- Erionite
- Ethylene oxide
- Etoposide alone and in combination with cisplatin and bleomycin
- Formaldehyde
- Gallium arsenide
- Helicobacter pylori (infection with)
- Hepatitis B virus (chronic infection with)
- Hepatitis C virus (chronic infection with)
- Herbal remedies containing plant species of the genus Aristolochia
- Human immunodeficiency virus type 1 (infection with)
- Human papillomavirus type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66
- Human T-cell lymphotropic virus type I
- Melphalan
- Methoxsalen (8-Methoxypsoralen) plus ultraviolet A radiation
- 4,4’-methylene-bis(2-chloroaniline) (MOCA)
- MOPP and other combined chemotherapy including alkylating agents
- Mustard gas (Sulfur mustard)
- 2-Naphthylamine
- Neutron radiation
- Nickel compounds2
- 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK)
- N-Nitrosonornicotine (NNN)
- Opisthorchis viverrini (infection with)
- Phosphorus-32, as phosphate
- Plutonium-239 and its decay products (may contain plutonium-240 and other isotopes), as aerosols
- Radioiodines, short-lived isotopes, including iodine-131, from atomic reactor accidents and nuclear weapons detonation (exposure during childhood)
- Radionuclides, α-particle-emitting, internally deposited4
- Radionuclides, β-particle-emitting, internally deposited4
- Radium-224 and its decay products
- Radium-226 and its decay products
- Radium-228 and its decay products
- Radon-222 and its decay products
- Schistosoma haematobium (infection with)
- Silica, crystalline (inhaled in the form of quartz or cristobalite from occupational sources)
- Solar radiation
- Talc containing asbestiform fibres
- Tamoxifen5
- 2,3,7,8-Tetrachlorodibenzo-para-dioxin
- Thiotepa (1,1',1"-Phosphinothioylidynetrisaziridine)
- Thorium-232 and its decay products, administered intravenously as a colloidal dispersion of thorium-232 dioxide
- Treosulfan
- ortho-Toluidine
- Vinyl chloride
- Ultraviolet Radiation
- X-Radiation and Gamma radiation
[edit] Mixtures
[edit] Exposure circumstances
[edit] Notes and references
- This evaluation applies to the group of compounds as a whole and not necessarily to all individual compounds within the group.
- Evaluated as a group.
- There is also conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium.
- Specific radionuclides for which there is sufficient evidence for carcinogenicity to humans are also listed individually as Group 1 agents.
- There is also conclusive evidence that this agent (tamoxifen) reduces the risk of contralateral breast cancer.
[edit] External links
|
|
|
| Main articles |
|
|
| Major suspected carcinogens |
|
|
| IARC |
|
|
|
|
|